1. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
- Author
-
Hoff NA, Bratcher A, Kelly JD, Musene K, Kompany JP, Kabamba M, Mbala-Kingebeni P, Dighero-Kemp B, Kocher G, Elliott E, Reilly C, Halbrook M, Ilunga Kebela B, Gadoth A, Ngoie Mwamba G, Tambu M, McIlwain DR, Mukadi P, Hensley LE, Ahuka-Mundeke S, Rutherford GW, Muyembe-Tamfum JJ, and Rimoin AW
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral immunology, Child, Democratic Republic of the Congo, Disease Outbreaks prevention & control, Female, Glycoproteins immunology, Humans, Male, Middle Aged, Seroepidemiologic Studies, Vaccination methods, Viral Envelope Proteins immunology, Young Adult, Ebola Vaccines immunology, Ebolavirus immunology, Hemorrhagic Fever, Ebola immunology, Immunogenicity, Vaccine immunology
- Abstract
Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examines the antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among EVD-exposed and potentially exposed populations in the DRC. We conducted a longitudinal cohort study of 608 rVSVΔG-ZEBOV-GP-vaccinated individuals during an EVD outbreak in North Kivu Province, DRC. Participants provided questionnaires and blood samples at three study visits (day 0, visit 1; day 21, visit 2; and month 6, visit 3). Anti-GP immunoglobulin G (IgG) antibody titers were measured in serum by the Filovirus Animal Nonclinical Group anti-Ebola virus GP IgG enzyme-linked immunosorbent assay. Antibody response was defined as an antibody titer that had increased fourfold from visit 1 to visit 2 and was above four times the lower limit of quantification at visit 2; antibody persistence was defined as a similar increase from visit 1 to visit 3. We then examined demographics for associations with follow-up antibody titers using generalized linear mixed models. A majority of the sample, 87.2%, had an antibody response at visit 2, and 95.6% demonstrated antibody persistence at visit 3. Being female and of young age was predictive of a higher antibody titer postvaccination. Antibody response and persistence after Ebola vaccination was robust in this cohort, confirming findings from outside of the DRC., Competing Interests: The authors declare no competing interest., (Copyright © 2022 the Author(s). Published by PNAS.)
- Published
- 2022
- Full Text
- View/download PDF